Crinetics Pharmaceuticals Inc. (CRNX) is scheduled to make a presentation related to its drug candidate Atumelnant at the Endocrine Society's annual meeting on June 3, 2024.
Atumelnant, an oral, selective ACTH antagonist, is in development for the treatment of ACTH-dependent Cushing's syndrome and congenital adrenal hyperplasia (CAH).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com